Experimental Renal Cell Carcinoma Combination Treatment Shows Promise in Early Trial
source: pixabay.com

Experimental Renal Cell Carcinoma Combination Treatment Shows Promise in Early Trial

According to a story from Targeted Oncology, an experimental combination therapy tested on patients with advanced clear cell renal cell carcinoma (ccRCC) appeared to show potential for efficacy in a…

Continue Reading Experimental Renal Cell Carcinoma Combination Treatment Shows Promise in Early Trial
Opdivo-Yervoy Combination Improves 4-Year Survival for Patients with RCC
source: pixabay.com

Opdivo-Yervoy Combination Improves 4-Year Survival for Patients with RCC

  This past week, Bristol Myers Squibb shared four-year data from the Phase 3 CheckMate-214 clinical trial. Ultimately, the trial sought to understand the safety, efficacy, and tolerability of Opdivo…

Continue Reading Opdivo-Yervoy Combination Improves 4-Year Survival for Patients with RCC
MK-6482 Receives Breakthrough Therapy Designation for VHL-Related RCC
Photo by Robina Weermeijer on Unsplash

MK-6482 Receives Breakthrough Therapy Designation for VHL-Related RCC

  According to Ryan McDonald of Cure Today, the FDA recently granted Breakthrough Therapy Designation to MK-6482, an investigational HIF-2α inhibitor developed by Merck. The orally-administered drug, designed to treat…

Continue Reading MK-6482 Receives Breakthrough Therapy Designation for VHL-Related RCC
Recent Study Suggests Changes to Renal Cell Carcinoma Staging Classification
source: pixabay.com

Recent Study Suggests Changes to Renal Cell Carcinoma Staging Classification

According to a story from Medscape, a recent cohort study published in the journal Cancer has concluded that updates are needed to the staging classification currently in use for renal cell carcinoma…

Continue Reading Recent Study Suggests Changes to Renal Cell Carcinoma Staging Classification
More Renal Cell Carcinoma Treatments Improve Patient Outcomes: George and Shaun’s Stories
qimono / Pixabay

More Renal Cell Carcinoma Treatments Improve Patient Outcomes: George and Shaun’s Stories

  "I thought it was a hernia." When George Benson experienced lower abdominal pain in 2009, at age 51, he wasn't concerned. He was a truck driver, artist, and family…

Continue Reading More Renal Cell Carcinoma Treatments Improve Patient Outcomes: George and Shaun’s Stories

Biotherapeutics Reduced This Patient’s Tumors After Seven Other Therapies Failed

A recent Biospace article covers a news release from 4D Pharma in Leeds, England. 4D has announced the first worldwide clinical confirmation of a biotherapeutic product. MRx0518 has been combined…

Continue Reading Biotherapeutics Reduced This Patient’s Tumors After Seven Other Therapies Failed

‘No Cure, No Pay’ Model in the Netherlands Means Patients Don’t Pay Unless Their Therapy Works

No Cure, No Pay Emile Voest, an oncologist in the Netherlands, conceived the idea of a no cure, no pay model. After witnessing the exorbitant cost of drugs, some of…

Continue Reading ‘No Cure, No Pay’ Model in the Netherlands Means Patients Don’t Pay Unless Their Therapy Works
New Collaboration Will Test Live Biotherapeutics Against Different Cancers
geralt / Pixabay

New Collaboration Will Test Live Biotherapeutics Against Different Cancers

According to a story from finanznachrichten.de, the biotherapeutics company 4D pharma has recently announced a research partnership with the MD Anderson Cancer Center at the University of Texas. The goal of…

Continue Reading New Collaboration Will Test Live Biotherapeutics Against Different Cancers

New Resources Could Improve Drug Development for Fibrodysplasia Ossificans Progressiva

Ipsen has just announced that they will be acquiring Clementia Pharmaceuticals. This merging of companies is exciting for the rare community because it will strengthen the resources, knowledge-base, and overall…

Continue Reading New Resources Could Improve Drug Development for Fibrodysplasia Ossificans Progressiva

Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma

  The treatment of metastatic renal cell carcinoma (RCC) has evolved over the last ten years and investigators now look towards combination therapies to improve response rates and durability for…

Continue Reading Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma
FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
Source: Pixabay.com

FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients

According to an article from Global Banking & Financing Review, the California-based pharmaceutical company Exelixis, Inc. has announced the FDA's approval of their drug Cabometyx (cabozantinib) for patients previously diagnosed…

Continue Reading FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
New Combination Therapy for Renal Cell Carcinoma Gains European Approval
source: pixabay.com

New Combination Therapy for Renal Cell Carcinoma Gains European Approval

According to a story from BioPortfolio, the Bristol-Myers Squibb Company recently announced that the European Commission has recently approved the first combination treatment for renal cell carcinoma available in the…

Continue Reading New Combination Therapy for Renal Cell Carcinoma Gains European Approval
Interim Trial Data Released for Potential Renal Cell Carcinoma Treatment Announced
source: pixabay

Interim Trial Data Released for Potential Renal Cell Carcinoma Treatment Announced

According to a story from BioSpace, EUSA Pharma and AVEO Oncology recently announced the release of updated interim results from the second Phase of a Phase Ib/2 clinical trial which…

Continue Reading Interim Trial Data Released for Potential Renal Cell Carcinoma Treatment Announced

Recent Discovery Could Lead to New Treatment Approach for Renal Cell Carcinoma

According to a story from Science Daily, researchers have discovered a mechanism that drives the development of renal cell carcinoma. This mechanism could lead to new therapeutic approaches that take…

Continue Reading Recent Discovery Could Lead to New Treatment Approach for Renal Cell Carcinoma
American Society for Clinical Oncology’s Annual Meeting: Summary of Rare Cancer Findings
jarmoluk / Pixabay

American Society for Clinical Oncology’s Annual Meeting: Summary of Rare Cancer Findings

According to a story from currentargus.com, the annual meeting of the American Society for Clinical Oncology, which takes place in Chicago, is the largest convergence dedicated to cancer research in…

Continue Reading American Society for Clinical Oncology’s Annual Meeting: Summary of Rare Cancer Findings
Pfizer is Likely to Halt It’s Phase 3 Trial of a Treatment for Recurrent Kidney Cancer Following Disappointing Results
Source: Pixabay

Pfizer is Likely to Halt It’s Phase 3 Trial of a Treatment for Recurrent Kidney Cancer Following Disappointing Results

The phase 3 trial of the drug Inlyta for the treatment of patients with a high risk of recurrent renal cell carcinoma (kidney cancer) following nephrectomy (removal of a kidney)…

Continue Reading Pfizer is Likely to Halt It’s Phase 3 Trial of a Treatment for Recurrent Kidney Cancer Following Disappointing Results
TNF Inhibitors May Put Children at Risk For Rare Cancers, Study Says
Source: pixabay.com

TNF Inhibitors May Put Children at Risk For Rare Cancers, Study Says

According to an article from Righting Injustice, a recent study suggests that TNF inhibitors may increase the risk of rare cancers in pediatric patients. The study recommends that children that…

Continue Reading TNF Inhibitors May Put Children at Risk For Rare Cancers, Study Says
This Inspirational Irish Man’s Cancer Returned Again, But Now He is Raising Money For Treatment
witwiccan / Pixabay

This Inspirational Irish Man’s Cancer Returned Again, But Now He is Raising Money For Treatment

Michael Mullan was only a baby when he was diagnosed with cancer for the first time-- specifically neuroblastoma, a childhood cancer which had a low survival rate. Since then, he…

Continue Reading This Inspirational Irish Man’s Cancer Returned Again, But Now He is Raising Money For Treatment
The European Commission Just Approved MVASI, One of The First Biosimilar Cancer Drugs
source: pixabay.com

The European Commission Just Approved MVASI, One of The First Biosimilar Cancer Drugs

According to an article from PRNewswire, the drug MVASI (biosimilar bevacizumab) was just granted marketing authorization by the European Commission. Developed by Amgen and Allergan, this treatment has been approved…

Continue Reading The European Commission Just Approved MVASI, One of The First Biosimilar Cancer Drugs
New Combination Treatment Could Improve Outcomes In Renal Cell Carcinoma
source: pixabay.com

New Combination Treatment Could Improve Outcomes In Renal Cell Carcinoma

According to an article at publicnow.com, the FDA has granted Breakthrough Therapy Designation to avelumab combined with INLYTA (axitinib) for people with advanced renal cell carcinoma. This designation should accelerate…

Continue Reading New Combination Treatment Could Improve Outcomes In Renal Cell Carcinoma
Close Menu